Gastric Insufflation and Laryngeal Mask Airway

Gastric Insufflation Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02097771
• Other study ID #: 2013-A01852-43
• Status: Recruiting
• Phase: N/A
• First received: March 21, 2014
• Last updated: November 18, 2014
• Start date: November 2014

Study information

• Verified date: November 2014
• Source: Hôpital Edouard Herriot
• Contact: Lionel Bouvet
• Phone: +33 4 72 11 69 88
• Email: lionel.bouvet[@]chu-lyon.fr
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé
• Study type: Interventional

Clinical Trial Summary

Comparison of the incidence of gastric insufflation between two kinds of laryngeal masks airways: LMA SupremeTM vs Ambu AuraOnceTM

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 0
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 95 Years

Eligibility

Inclusion Criteria:

• ASA 1 or 2

• Age > 18 yrs

• Use of laryngeal mask airway required

Exclusion Criteria:

• risk of pulmonary aspiration of gastric contents

• Contraindication for the use of laryngeal mask airway

• Tracheal intubation required

• Patient's refusal

Study Design

Allocation: Randomized

Related Conditions & MeSH terms

• Gastric Insufflation

Intervention

Device:
• LMA SupremeTM

• AuraOnceTM

Locations

Country	Name	City	State
France	Hospices Civils de Lyon	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Lionel Bouvet

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	incidence of gastric insufflation		during pulmonary ventilation through the laryngeal mask airway